HighTower Advisors
ESPR

HighTower Advisors’s Esperion Therapeutics ESPR Stock Holding History

HighTower Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,500
Closed -$6.18K – 3844
2024
Q4 		$6.18K Buy
19,500
+2,500
+15% +$5.83K ﹤0.01% 3618
2024
Q3 		$4.25K Buy
17,000
+4,000
+31% +$8.08K ﹤0.01% 3601
2024
Q2 		$11.4K Buy
13,000
+2,800
+27% +$6.59K ﹤0.01% 3434
2024
Q1 		$3.54K Buy
+10,200
New +$24.8K ﹤0.01% 3459
2020
Q3 		– Sell
-1,000
Closed -$22K – 2588
2020
Q2 		$22K Sell
1,000
-2,400
-71% -$100K ﹤0.01% 2253
2020
Q1 		$30K Buy
3,400
+600
+21% +$31.7K ﹤0.01% 2048
2019
Q4 		$83K Buy
2,800
+600
+27% +$27K ﹤0.01% 2092
2019
Q3 		$25K Buy
+2,200
New +$87.1K ﹤0.01% 2256

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

HighTower Advisors's ESPR Position: Q2 2026 in Review

HighTower Advisors reduced its Esperion Therapeutics (ESPR) stake by 91% in Q2 2026, selling an estimated $358K and leaving 13,021 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3739.

HighTower Advisors first reported a position in ESPR in Q3 2018 and has held it in 22 quarters since. The position peaked at $1.3M in Q2 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • HighTower Advisors held 13,021 shares of Esperion Therapeutics worth $41.1K as of Q2 2026.
  • HighTower Advisors sold 128,131 Esperion Therapeutics shares in Q2 2026, an estimated $358K.
  • Esperion Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3739 holding.
  • HighTower Advisors first reported a position in Esperion Therapeutics in Q3 2018 and has held it in 22 quarters since.
  • HighTower Advisors's Esperion Therapeutics position peaked at $1.3M in Q2 2019.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.